

A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis

NCT03773965

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	190 participants

Key Eligibility Criteria

Inclusion (1)

- Participants must have completed a previous study of baricitinib for the treatment of JIA.

Exclusion (2)

- Participants must not have had a permanent discontinuation of baricitinib in the prior study.
- Participants must have not developed an allergy to baricitinib.

Locations (82 total)

Instituto CAICI SRL, Rosario, Argentina
Centro de Investigaciones Médicas Tucuman, SAN M. de Tucuman, Argentina
Royal Children's Hospital, Melbourne, Australia
... and 79 more locations